AstraZeneca on Thursday provided insight on an ongoing China probe into the company concerning alleged illegal drug imports, ...

Bristol Myers Squibb announces $2B in new cost cuts over 3 years, including workforce reductions, following $1.5B cuts in ...

Eli Lilly reports 45% Q4 revenue jump to $13.53B, missing projections. Company maintains 2025 revenue outlook of $58-61B amid competition with Novo Nordisk in obesity market.

Many Americans have flocked to cheaper, compounded versions of GLP-1 weight loss drugs in lieu of brand-name treatments. That ...

EyePoint's Duravyu meets primary endpoint in Phase 2 DME trial, showing potential to compete with Regeneron's Eylea and Roche ...

Revance Therapeutics accepts Crown Laboratories' $3.65/share acquisition offer over rival bid from Teoxane, ending battle for ...

Alys Pharmaceuticals is on the hunt for a large financing to carry forward its pipeline — an amalgamation of six Medicxi ...

GSK said it is holding steady in the face of ongoing regulatory and potential political pressures on its vaccines franchise, ...

All nine late-stage kidney cancer patients in a Phase 1 trial of a personalized vaccine remained cancer-free after more than three years of receiving treatment, researchers wrote in a Nature paper ...

Bristol Myers Squibb cuts 67 jobs in Lawrence Township, NJ, while Kyowa Kirin lays off 52 employees at Princeton facility, per NJ WARN notices.

Amgen's obesity drug AMG-513 on clinical hold; company reaffirms obesity market ambitions while advancing MariTide program ...

Astellas is reorganizing its management team, and while it doesn't involve a change at the top as Daiichi Sankyo announced ...